Kirkpatrick, J., Vredenburgh, J. J., Reardon, D. A., Desjardins, A., Peters, K., Gururangan, S., … Friedman, H. S. (2010). Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas. Journal of Clinical Oncology, 28(15_suppl), 2073–2073. https://doi.org/10.1200/jco.2010.28.15_suppl.2073

Kirkpatrick, J., J. J. Vredenburgh, D. A. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. E. Herndon, J. Marcello, S. Woodring, and H. S. Friedman. “Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2073–2073. https://doi.org/10.1200/jco.2010.28.15_suppl.2073.

Kirkpatrick J, Vredenburgh JJ, Reardon DA, Desjardins A, Peters K, Gururangan S, et al. Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):2073–2073.

Kirkpatrick, J., et al. “Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 2073–2073. Crossref, doi:10.1200/jco.2010.28.15_suppl.2073.

Kirkpatrick J, Vredenburgh JJ, Reardon DA, Desjardins A, Peters K, Gururangan S, Herndon JE, Marcello J, Woodring S, Friedman HS. Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):2073–2073.